The Institute for Cannabinoid Research Translational Medicine (ICR) is an interdisciplinary group that unites researchers, clinicians, and scientists from across the globe with a shared goal of advancing medical solutions.
The ICR's mission consists of three key objectives: (1) to encourage research into cannabinoids; (2) to facilitate the sharing of scientific knowledge and diverse perspectives on Cannabis, cannabinoids, and endocannabinoids by hosting scientific conferences; and (3) to act as a dependable resource for information on the chemistry, pharmacology, therapeutic applications, toxicology, and the behavioral, psychological, and social impacts of Cannabis and its components and terpenes, as well as synthetic and endogenous substances that engage with cannabinoid receptors or target other elements of the endocannabinoid system.
The ICR is a non-political, secular organization committed to unbiased scientific inquiry across all areas of cannabinoid and terpene research—ranging from biochemical, chemical, and physiological investigations of the endocannabinoid system to studies on the misuse potential of non-medical Cannabis. Beyond offering impartial information about Cannabis and cannabinoids and terpeneoids, the ICR's primary function is to create an open space where researchers can convene and exchange ideas about their work.
Mission
To foster international collaboration and advance scientific understanding of cannabinoids and terpenoids and the Endocannabinoid System.
Activities
Research, development, education, consulting, and public awareness initiatives.
Scientific Advisory Counseling
ICR is in close connection for further education and guidance with globally recognized experts in biochemistry, molecular biology, neurotoxicology, physiology, cannabinoid and terpenoid pharmacology, oncology and translational medicine.
ICR extends its scientific data and logic thanks to the respectful gratitude to the pioneers Sean Munro (Molecular Biology, Cambridge, UK), Tom I. Bonner (National Institutes of Health NIH, US), Mauro Maccarrone (University of L'Aquila, Italy), Vincenzo Di Marzo (Université Laval, Canada), Roger Pertwee (University of Aberdeen, UK), Dale Deutsch (Professor Emeritus, Stony Brook University) and Allyn Howlett (Wake Forest School of Medicine, Winston-Salem).
